Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies.

IF 2.2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Clinical Trials Pub Date : 2024-04-01 Epub Date: 2023-11-20 DOI:10.1177/17407745231207858
Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard
{"title":"Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies.","authors":"Bart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, Patrick Darken, Simon Lennard","doi":"10.1177/17407745231207858","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High-quality decision-making in the pharmaceutical industry requires accurate assessments of the Probability of Technical Success of clinical trials. Failure to do so will lead to lost opportunities for both patients and investors. Pharmaceutical companies employ different methodologies to determine Probability of Technical Success values. Some companies use power and assurance calculations; others prefer to use industry benchmarks with or without the overlay of subjective modulations. At AstraZeneca, both assurance calculations and industry benchmarks are used, and both methods are combined with modulations.</p><p><strong>Methods: </strong>AstraZeneca has recently implemented a simple algorithm that allows for modulation of a Probability of Technical Success value. The algorithm is based on a set of multiple-choice questions. These questions cover a comprehensive set of issues that have historically been considered by AstraZeneca when subjective modulations to Probability of Technical Success values were made but do so in a much more structured way.</p><p><strong>Results: </strong>A set of 57 phase 3 Probability of Technical Success assessments suggests that AstraZeneca's historical estimation of Probability of Technical Success has been reasonably accurate. A good correlation between the subjective modulation and the modulation algorithm was found. This latter observation, combined with the finding that historically AstraZeneca has been reasonably accurate in its estimation of Probability of Technical Success, gives confidence in the validity of the novel method.</p><p><strong>Discussion: </strong>Although it is too early to demonstrate whether the method has improved the accuracy of company's Probability of Technical Success assessments, we present our data and analysis here in the hope that it may assist the pharmaceutical industry in addressing this key challenge. This new methodology, developed for pivotal studies, enables AstraZeneca to develop more consistent Probability of Technical Success assessments with less effort and can be used to adjust benchmarks as well as assurance calculations.</p><p><strong>Conclusion: </strong>The Probability of Technical Success modulation algorithm addresses several concerns generally associated with assurance calculations or benchmark without modulation: selection biases, situations where little relevant prior data are available and the difficulty to model many factors affecting study outcomes. As opposed to using industry benchmarks, the Probability of Technical Success modulation algorithm allows to accommodate project-specific considerations.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"220-232"},"PeriodicalIF":2.2000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17407745231207858","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: High-quality decision-making in the pharmaceutical industry requires accurate assessments of the Probability of Technical Success of clinical trials. Failure to do so will lead to lost opportunities for both patients and investors. Pharmaceutical companies employ different methodologies to determine Probability of Technical Success values. Some companies use power and assurance calculations; others prefer to use industry benchmarks with or without the overlay of subjective modulations. At AstraZeneca, both assurance calculations and industry benchmarks are used, and both methods are combined with modulations.

Methods: AstraZeneca has recently implemented a simple algorithm that allows for modulation of a Probability of Technical Success value. The algorithm is based on a set of multiple-choice questions. These questions cover a comprehensive set of issues that have historically been considered by AstraZeneca when subjective modulations to Probability of Technical Success values were made but do so in a much more structured way.

Results: A set of 57 phase 3 Probability of Technical Success assessments suggests that AstraZeneca's historical estimation of Probability of Technical Success has been reasonably accurate. A good correlation between the subjective modulation and the modulation algorithm was found. This latter observation, combined with the finding that historically AstraZeneca has been reasonably accurate in its estimation of Probability of Technical Success, gives confidence in the validity of the novel method.

Discussion: Although it is too early to demonstrate whether the method has improved the accuracy of company's Probability of Technical Success assessments, we present our data and analysis here in the hope that it may assist the pharmaceutical industry in addressing this key challenge. This new methodology, developed for pivotal studies, enables AstraZeneca to develop more consistent Probability of Technical Success assessments with less effort and can be used to adjust benchmarks as well as assurance calculations.

Conclusion: The Probability of Technical Success modulation algorithm addresses several concerns generally associated with assurance calculations or benchmark without modulation: selection biases, situations where little relevant prior data are available and the difficulty to model many factors affecting study outcomes. As opposed to using industry benchmarks, the Probability of Technical Success modulation algorithm allows to accommodate project-specific considerations.

算法基准调制:开发临床研究成功率的新方法。
背景:制药业要做出高质量的决策,就必须准确评估临床试验的技术成功概率。如果做不到这一点,患者和投资者都将错失良机。制药公司采用不同的方法来确定技术成功概率值。一些公司使用功率和保证计算;而另一些公司则更倾向于使用行业基准,并附加或不附加主观调节。在阿斯利康公司,保证计算和行业基准都被采用,而且这两种方法都与调制方法相结合:阿斯利康最近采用了一种简单的算法,可以对技术成功概率值进行调节。该算法基于一组多项选择题。这些问题涵盖了阿斯利康历来在对技术成功概率值进行主观调节时所考虑的一系列问题,但这些问题的处理方式更有条理:一组 57 项第三阶段技术成功概率评估结果表明,阿斯利康对技术成功概率的历史估计相当准确。主观调制与调制算法之间存在良好的相关性。后一项观察结果与阿斯利康公司历来对技术成功概率的估计相当准确这一结论相结合,使人们对新方法的有效性充满信心:虽然现在证明该方法是否提高了公司技术成功概率评估的准确性还为时尚早,但我们在此提出我们的数据和分析,希望能帮助制药行业应对这一关键挑战。这种为关键性研究开发的新方法使阿斯利康能够以更少的工作量开发出更一致的技术成功概率评估,并可用于调整基准和保证计算:技术成功概率调节算法解决了通常与保证计算或无调节基准相关的几个问题:选择偏差、可用相关先前数据较少的情况以及难以模拟影响研究结果的多种因素。与使用行业基准不同的是,技术成功概率调节算法允许考虑项目的具体因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Trials
Clinical Trials 医学-医学:研究与实验
CiteScore
4.10
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Clinical Trials is dedicated to advancing knowledge on the design and conduct of clinical trials related research methodologies. Covering the design, conduct, analysis, synthesis and evaluation of key methodologies, the journal remains on the cusp of the latest topics, including ethics, regulation and policy impact.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信